Title:
LONG-ACTING RECOMBINANT HUMAN INTERFERON Α2B-FC FUSION PROTEIN
Document Type and Number:
WIPO Patent Application WO/2015/161832
Kind Code:
A1
Abstract:
Provided is a human interferon α2b-Fc fusion protein, wherein the C-terminal of the human interferon α2b is linked to the N-terminal of Fc by a peptidic linker. Provided is a nucleic acid sequence encoding the fusion protein and a eukaryotic expression system expressing the fusion protein. Also provided is a use of the fusion protein in the preparation of an antiviral or antitumour drug. The fusion protein has an improved antiviral activity and prolonged in vivo half-life.
Inventors:
ZHU WENCHEN (CN)
ZHU CHENGGONG (CN)
ZHU LUYAN (CN)
ZHU SHIQIAO (CN)
WANG XIAOSHAN (CN)
LIU BING (CN)
REN ZIJIA (CN)
ZHU SONGLIN (CN)
SUN NAICHAO (CN)
LI QIANG (CN)
SU HONGSHENG (CN)
MENG QINGLE (CN)
CUI HAO (CN)
ZHU CHENGGONG (CN)
ZHU LUYAN (CN)
ZHU SHIQIAO (CN)
WANG XIAOSHAN (CN)
LIU BING (CN)
REN ZIJIA (CN)
ZHU SONGLIN (CN)
SUN NAICHAO (CN)
LI QIANG (CN)
SU HONGSHENG (CN)
MENG QINGLE (CN)
CUI HAO (CN)
Application Number:
PCT/CN2015/077504
Publication Date:
October 29, 2015
Filing Date:
April 27, 2015
Export Citation:
Assignee:
FUREN PHARMACEUTICAL GROUP CO LTD (CN)
HENAN FUREN PHARMACEUTICAL TECHNOLOGY DEV CO LTD (CN)
HENAN FUREN PHARMACEUTICAL TECHNOLOGY DEV CO LTD (CN)
International Classes:
C07K19/00; A61K38/21; A61K39/395; A61P31/12; A61P35/00; C07K14/56; C12N15/62; C12N15/85
Foreign References:
| CN1206350A | 1999-01-27 |
Other References:
WANG, LEI ET AL.: "Enhanced Circulation Half-life for Human IFNa2b and IgG Fc Fusion Protein", CHINESE JOURNAL OF BIOTECHNOLOGY, vol. 24, no. 1, 25 January 2008 (2008-01-25), XP008134213
Attorney, Agent or Firm:
PATENTSINO IP FIRM (CN)
北京柏杉松知识产权代理事务所（普通合伙） (CN)
北京柏杉松知识产权代理事务所（普通合伙） (CN)
Download PDF: